APM - Aptorum Group partners with Yale University for immunomodulators development; stock +6%

Aptorum Group (APM) is up 6% premarket after announcing material transfer and option agreement with Yale University for the preclinical stage development of its novel immunomodulators, potentially targeting autoimmune and oncology diseases.Under the arrangement, Aptorum will be responsible for assessing Yale’s originally developed novel immunomodulators against lupus, arthritis, inflammatory bowel diseases, neurodegenerative diseases or other oncology indications. In addition, the exclusive option to in-license the novel immunomodulators and its affiliated intellectual property rights will allow Aptorum to develop and commercialize."Aptorum is delighted to partner with Yale to validate and develop its novel class of immunomodulators. Aptorum believes that these immunomodulators have the potential to advance first-in-class drug discovery and development of such drugs for potential autoimmune and oncology diseases in particular. For example, it has been widely reported that COVID-19 infections often trigger a cytokine storm in patients leading to undesirable and often fatal autoiummune reactions1 and we will also explore the potential applications of

For further details see:

Aptorum Group partners with Yale University for immunomodulators development; stock +6%